Tc 99m NC 100586

Drug Profile

Tc 99m NC 100586

Alternative Names: 99m-Tc-NC100586

Latest Information Update: 08 Sep 2006

Price : $50

At a glance

  • Originator GE Healthcare; Targeted Diagnostics and Therapeutics
  • Developer GE Healthcare; Targeted Diagnostics and Therapeutics; Thomas Jefferson University
  • Class Heavy metals; Radiopharmaceuticals
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 08 Sep 2006 Discontinued - Preclinical for Solid tumour diagnosis in USA (IV)
  • 16 Apr 2004 Amersham has merged with GE Medical Systems to form GE Healthcare
  • 14 Nov 2002 A preclinical study has been added to the pharmacokinetics and Cancer pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top